Third Circuit Won’t Revive AstraZeneca’s Challenge to Medicare Drug Price Negotiation Program
- May 09, 2025
The Third Circuit declined May 8 to revive AstraZeneca Pharmaceuticals LP’s bid to challenge the Medicare drug price negotiation program as unconstitutional.
ARTICLE TAGS
You must be logged in to access this content.